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Abstract
Aortic aneurysm is defined as a pathologically dilated segment of the main artery. There are three main types 
of aortic aneurysms: real, pseudo and dissecting. The most common aneurysms are abdominal aortic aneu-
rysms defined as vasodilatation equal to or above 30 mm. Abdominal aortic aneurysm development is usually 
asymptomatic. Many various risk factors have been linked to AAA development. The pathophysiology of AAA 
is associated with inflammation, smooth muscle cells apoptosis and matrix degradation. The changes always 
result from imbalance between active matrix metalloproteinases (MMPs) and their inhibitors — TIMPs.
Abdominal aorta is the most common location for the aneurysm. The risk of developing AAA increases with 
age. It is more common in men. Its rupture is associated with a high risk of death. The pathogenesis of AAA is 
complex and still not fully understood. In pathophysiological processes, aortic wall degeneration and athero-
sclerosis dominate. The factors involved in the pathogenesis of AAA and TAA are not quite the same. Important 
factors involved in the formation of AAA and increasing the risk of its rupture are MMPs. Also, polymorphisms 
of numerous genes have been associated with the risk of developing AAA. The two groups of factors related to 
AAA formation and development are presented and discussed in this work.
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Introduction
Aortic aneurysm is defined as pathologically dilated 
segment of the main artery with loss of parallelism in 
its wall layers and at least 50% wider diameter of the 
affected artery than expected in persons of the same 
age and same sex [1, 2]. The correct dimensions of the 
aorta in adults, measured from the outer edge of the 
contour, are listed in Table 1.
 The first description of the abdominal aortic an-
eurysm has been provided already in the 16th century 
by Vesalius [3]. In the first half of the 20th century, 
unsuccessful attempts were made to treat AAAs by 
various surgical methods. The first successful surgery 
of AAA with aortic reconstruction using corpse vessels 
was carried out by Dubost in 1951 [4]. In 1965, Cooley 
and DeBakey introduced surgery for ascending aortic 
aneurysms, while in 1986 Volodos was the first who 
implanted a stentgraft in to the abdominal aorta [5, 6].
The classification of aortic aneurysms is based 
on different criteria. There are three main types of 
aortic aneurysms: real aneurysm, pseudoaneurism 
and dissecting aneurysm. In terms of histological 
structure, aortic aneurysms can be divided into two 
major groups baggy and fusiform. Both are true 
aneurysms and include all layers of the aortic wall. 
Fusiform aneurysms are more common. They are 
manifested by symmetrical widening covering the 
entire aortic circumference. Baggy aneurysms are 
less common. They are characterized by local bulge. 
The clinical division of aortic aneurysms is based on 
their location – thoracic aortic aneurysm (TAA) and 
abdominal aortic aneurysm (AAA). This division is 
important because these aneurysms are treated by 
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various medical specialties [7]. The division and clas-
sification of aortic aneurysms is presented in Table 2.
 The most common aneurysms are abdominal aortic 
aneurysms, which are defined as vasodilatation equal 
or above 30 mm. Infrarenal aneurysms make up 90% 
of all aortic aneurysms. The incidence of AAA is gen-
der-specific. Men are more likely to suffer from AAA. 
It is estimated that 3 to 9% of men over 50 years of 
age develop AAA, while the percentage for women 
over 55 years of age is 1 to 2%. The epidemiological 
data indicate that the incidence of AAA increases with 
age. The AAA is rare in people under the age of 50; 
however, 12.5% of men and 5.2% of women aged 74 
to 84 do develop AAA [8–10].
Abdominal aortic aneurysm is usually not accompa-
nied by any specific symptoms. If any, the most common 
symptoms are permanent, crushing pains in the lower 
abdomen or lumbar region. Possible are pains that re-
semble spinal root pains, but the movement does not 
affect the intensity of the pain. AAA with a diameter 
above 5 cm may be palpated for physical examination. 
Often, such an aneurysm is tender, especially when it 
increases rapidly. However, no relationship between 
palpation and increased risk of AAA rupture has been 
associated. In auscultation, murmurs over the abdom-
inal aorta can be heard [7]. The scant clinical manifes-
tations of AAA result in high mortality in this disease. In 
addition, 78% of patients with AAA rupture die of this 
before reaching the hospital [11]. Before reaching the 
hospital [11]. Currently, the basic diagnostic methods 
for AAA detection are ultrasonography (USG) and 
computed tomography (CT) of the abdominal cavity. 
Conservative treatment of AAA includes periodic 
ultrasound check-ups of the aneurysm, adequate control 
of blood pressure and lipid profile. The results of exper-
imental studies have shown that the administration of 
b-blockers favorably affects the metabolism and hemody-
namics of connective tissue and the durability of the aortic 
wall [11]. The main method of treating AAA is surgery. 
Every year, approximately 4.000 surgical procedures are 
performed in Poland for abdominal aortic aneurysm [12].
Abdominal aortic aneurysms increase their diame-
ter at different rates. AAAs with a diameter of 40 mm 
increase their diameter by about 2.6 mm/year, while 
those with a diameter of 60 mm by 6.5 mm/year. This is 
related to Laplace law. The risk of AAA rupture depends 
on its diameter [7, 8, 13] (Table 3).
AAA rupture is associated with a high risk of death 
of 65 to 90% [14]. It accounts for approximately 11,000 
deaths each year in the United States, with mortality 
rates from ruptured AAAs reaching up to 90% [13]. 
Moreover 2% of all deaths are AAA-related [10]. 
Smoking is a serious factor not only modulating AAA 
formation, but also affecting the expansion and rupture 
of the aneurysm. Smokers had a higher rate of annual 
increase in aneurysm diameter than former smokers 
and non-smokers. This is because the concentration 
of proteases, such as elastase, degrading elastin that is 
naturally present in the aortic wall increases [14, 15].
Numerous risk factors which can lead to AAA de-
velopment have been identified. Three most important 
ones are age (> 65 years), sex (males) and cigarette 
smoking [16, 17]. Researches proved a positive asso-
ciation between development of AAA and increasing 
years of smoking and a negative association with smok-
ing cessation [17]. Other risk factors include a family 
history of abdominal aortic aneurysm, coronary artery 
disease, arterial hypertension, hypercholesterolemia, 
peripheral artery disease (e.g., Takayasu inflammation), 
and previous myocardial infarction and other cardio-
Table 1. Normal aortic dimensions in adult [2]
Aortic segment Diameter (mm) Test method
Aortic valve ring W: 23 ± 2 USG (transthoracic)
M: 26 ± 3
Bay of Valsalva W: 30 ± 3 USG (transthoracic)
M: 34 ± 3
Pad of the aorta < 37 USG (transthoracic)
Ascending aorta (proximal part) W: 26 ± 3 USG (transesophageal)
M: 29 ± 3
Ascending aorta 14–21/m2 body surface USG (transesophageal)
25–38 tK
Descending aorta 10–16/m2 body surface USG (transesophageal)
17–28 tK
Abdominal aorta 14–21 USG, presentation B
W – woman; M – men; USG – ultrasound examination
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vascular diseases [18–20]. Moreover, excess weight 
was associated with increased risk, whereas, exercise 
and consumption of nuts, vegetables, and fruits were 
associated with reduced risk of AAA [17]. Risk factors 
of AAA are summarized in Figure 1. 
Structure of the abdominal aorta wall
The aorta is an elastic artery, which divides into 
three main parts: the ascending aorta, the arch of aorta 
and the descending aorta. The abdominal aorta is a part 
of the descending aorta, and it develops from splanchnic 
mesoderm [21, 22]. It starts at the aortic hiatus of the 
diaphragm and ends in aortic bifurcation. 
The aortic wall consists of three layers: outer ad-
ventitia, media, and inner intima (Fig. 2).
The intima has direct contact with blood. It is 
a single layer of endothelial cells upon loose connective 
tissue. It also has part called internal elastic lamina which 
consists of collagen and elastic fibers and a small amount 
of fibroblasts and smooth myocytes. The media is the 
widest layer; it consists of smooth muscle cells embed-
Table 2. Division and classification of aortic aneurysm
Division criteria Characteristics
Type of aortic aneurysms
Real aortic aneurysm Aortic pseudoaneurysm Aortic dissecting aneurysm
Localization  
of aortic aneurysms  
(clinical division)
Histological structure of the 
aortic aneurysms
Baggy aortic aneurysm Fusiform aortic aneurysm
Location of the abdominal 
aortic aneurysm
Infrarenal Juxtarenal Pararenal Suprarenal






Post traumatic  
aneurysm
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ded in a dense matrix of fibrillar structural proteins. 
The adventitia is made of connective tissue proper with 
a large number of collagen fibers, and fewer elastic 
fibers and smooth muscle cells. It also has ganglion cells 
and vasa vasorum — small blood vessels that supply the 
wall in nutrients. Their branches reach up to the border 
with tunica media [23, 24]. 
The aortic media provides viscoelasticity through 
concentric bands of elastin filaments with associated 
collagen fibers and smooth muscle cells (SMCs), which 
are termed lamellar units. The media of the abdominal 
aorta usually consists of 28 to 32 lamellar units and it 
is avascular – smooth muscle cells survival depends of 
transintimal nutrition and oxygen delivery from the 
plasma [25].
Pathogenesis of the abdominal 
aortic aneurysm 
The pathophysiology of AAA is accompanied by 
inflammation, SMC apoptosis and matrix degradation. 
Once considered a consequence of advanced athero-
sclerosis, evidence accumulated indicating that AAA is 
a focal representation of systemic cardiovascular disease 
[10]. Degenerative etiology dominates the pathogenesis 
of AAA, partly related to the atherosclerotic process 
[26]. In both AAA and TAA, the amount of elastin, col-
lagen and glycosaminoglycans are reduced compared to 
normal aortas. Imbalance between the amount of active 
MMPs and their inhibitors – TIMPs – are responsible for 
the majority of the above listed pathological changes 
[27, 28]. MMPs are members of the metzincin group 
of proteases, which are named due to the zinc ion and 
the conserved Met residue at the active site [29]. the 
main inhibitor of MMPs is glycoprotein — TIMP-1. The 
second TIMP is non-glycosylated protein, produced 
by fibroblasts and endothelial cells and called TIMP-2. 
TIMP-1 expression is regulated by interleukin 1 (IL-1) 
and tumor necrosis factor alpha (TNF-a). no effect 
of cytokines on TIMP-2 has been demonstrated [30]. 
Metalloproteinases in a healthy aorta are produced 
by endothelial cells, SMCs and fibroblasts. Additional 
sources of these enzymes were observed in AAA, which 
led to an imbalance in ratio of MMP to TIMP [31]. Dif-
ferent MMPs play a major role in the pathogenesis of 
TAA and AAA (Fig. 3).
In addition to the MMP/TIMP system, immune 
cells, the renin-angiotensin-aldosterone system, the 
inflammatory process and oxygen free radicals play an 
important role in the pathogenesis of AAA [31].
The role of MMP-1 in the pathogenesis  
of AAA
 Metalloproteinase 1 (collagenase 1; MMP-1) is an 
enzyme involved in the digestion of collagen fibers. In-
creased MMP-1 gene expression was found in patients 
with AAA while the level of its inhibitors was reduced 
[32]. Inflammatory cells are a small source of MMP-1 [33]. 
Table 3. Relationship between the risk of rupture of the  
abdominal aortic aneurysm on its diameter [7, 8, 13]
AAA diameter Risk of cracking during the year (%)





> 8 cm 30–50
An increase in AAA diameter by 5 mm in half a year increases the risk of rup-





AtherosclerosisEhlers — Danlos syndrome
Chronic obstructive pulmonary disease
Age > 75 years
Family history for AAA
Risk factors of AAA
Figure 1. Risk factors for abdominal aortic aneurysm (AAA) [13, 21]
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It has been shown that the presence of elevated MMP-
1 concentration in the aortic wall is associated with 
elevated risk of rupture [34].
The role of MMP-2 in the pathogenesis  
of AAA
The main role of MMP-2 in human tissue is degra-
dation of both type IV collagen, which is an important 
component of basal membranes, and denatured colla-
gen [35]. MMP-2’s role in abdominal aorta aneurysm 
relies on degradation of the intercellular substance of 
the aortic wall, which can lead to its rupture. Under 
normal conditions, the process of changes in vascular 
tissue is controlled by the balance between the action 
of MMP and their inhibition, which involves TIMPs. 
Increased expression of MMP-2 has been observed 
not only in the blood of patients suffering from AAA 
but also in the AAA tissue [16], which further increased 
the likelihood of AAA wall rapture.
The role of MMP-3 in the pathogenesis  
of AAA
MMP-3 (stromelysin 1) is responsible for digesting 
collagen and several other extracellular matrix pro-
teins, which are important in maintaining the structural 
integrity of the aortic wall and pericellular activation 
of proMMPs. For example it is necessary for trans-
formation of the proMPP-1 zymogen into fully active 
MMP-1. Immunohistochemical studies have previously 
revealed the expression of stromelysin-1 in abdominal 
aortic aneurysm in relation to macrophages present 
within the aortic wall. Thus, this additionally supported 
the idea that aneurysm expansion is due to a chronic 
inflammatory process [36].
Upregulation of stromelysin-1 and TIMP-3 expression 
may play a significant role in the expansion of an athero-
sclerotic aorta to form an aneurysm. It seems plausible that 
excessive production of stromelysin-1 in an atherosclerotic 
aorta weakens the aortic wall and causes additional prote-
olysis by activating other latent, constitutively expressed 
metalloproteinases [37]. MMP-3 contributes to plaque 
destabilization and promotes TAA formation by degrading 
the elastic lamina, and therefore plays an important role 
in aneurysm formation. MMP-3 was shown to degrade 
type IV collagen, fibronectin, laminin, proteoglycan core 
protein, and type IX collagen [38].
Results of genetic study revealed that the 5A allele 
in the promoter region of the MMP-3 gene occurs more 
frequently in AAA patients. This study also showed 
a link between the 5A/5A genotype and intensity of 
MMP-3 gene expression. The aortic aneurysmal wall 
of patients, who were homozygous for the 5A-allele, 
contained larger quantities (> 45%) of MMP-3 protein 
than the wall from 5A/6A heterozygotes; suggesting that 
the 5A-allele causes increase in MMP-3 production in 
these patients [39]. Meta-analysis of genes or putative 
AAA-related genes showed their positive correlation 
between MMP-3 rs3025058 polymorphism and a higher 
risk of AAA development [40].
The role of MMP-9 in the pathogenesis  
of AAA
MMP-9, also, called gelatinase B or type IV colla-
genase, is the metalloproteinase, which has three repeats 
of a type II fibronectin domain inserted in the catalytic 
domain through which the proteinase interacts with gela-
tin, collagens, and laminins [36]. Numerous cytokines are 
able to regulate MMP-9 expression, but the major role 
in it has TNF-a. At the transcriptional level an important 
positive regulator is nuclear factor-kB (nf-kB) [40]. ECM 
proteins which are proteolytically processed by MMP-9 
include collagen, elastin, fibronectin, and laminin [41].
MMP-9 is responsible for degradation of ECM pro-
teins at the aortic wall. In the pathogenesis of AAA, 
a major role has inflammatory response in the endothe-
lial, medial, and adventitial layers. Besides monocytes, 
other cells secreting MMP-9, such as macrophages and 
neutrophils, participate in this process. The activity of 
monocytes is modulated by proinflammatory cytokines, 
for example TNF-a, which can promote the secretion of 
MMPs via MAPK pathway [41]. Increased angiogenesis 
was also detected in the aneurysm wall [42] as a result 
of MMP-9-stimulated release of VEGF [43], the factor 
which stimulates angiogenesis.
Activation of TGF–b may be one of the ways in 
which MMP-2 and MMP-9 work together. Although 
it is generally believed that the activation of the TGF-
bsignaling pathway offers protection against AAA devel-
opment, it also has important roles in enhancing Type I 
and III collagen production, and increasing expression 
of protease inhibitors, plasminogen activator inhibitor-1 





Figure 2. Schematic structure of the abdominal aorta wall
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Correlation of MMP-9 concentration with maximum 
aortic diameter was considered a clinical marker of AAA 
growth. MMP-9 activity varies depending on the diame-
ter of the aorta. Its expression is increased in aneurysms 
with a diameter of 5 to 6 or even 9 cm [45, 46].
The role of MMP-12 in the pathogenesis 
of AAA
The main source of MMP-12 (metalloelastase) in the 
aortic wall are macrophages [47]. However, the role 
of this metalloproteinase in the pathogenesis of AAA 
is not completely understood. Results of experimental 
studies have shown that MMP-12 knockout (KO) mice 
have developed AAA. Interestingly, mice with KO of 
MMP-12 and MMP-9 and KO of MMP-9 alone did not 
develop AAA [48]. It is currently indicated that MMP-
12 cannot be directly involved in the pathogenesis of 
AAA but apparently helps other MMPs in extracellular 
matrix degradation [31].
The role of MMP-13 in the pathogenesis 
of AAA
The main source of MMP-13 (collagenase 3) are 
SMCs in the aortic wall. MMP-13 expression is increased 
in AAA people, especially in symptomatic AAA and in 
AAA with a high risk of rupture [49, 50] In genetic stud-
ies it has been shown that polymorphism (−77A/G) is 
a significant independent risk factor for AAA formation. 
These results indicated that MMP-13 plays an important 
role in the pathogenesis of AAA [31, 32].
The role of MMP-14 in the pathogenesis 
of AAA
MMP-14 (membrane type 1 MMP) is produced by 
macrophages and SMCs in the aortic wall. Clinical studies 
have shown that patients with AAA showed elevated 
MMP-14 gene expression [51]. Experimental studies have 
also shown that in mice with CaCl2-induced AAA MMP-14 
derived from macrophages played a key role in direct 
degradation of the extracellular matrix, which led to the 
development of AAA. It was found that MMP-14 directly 
regulated the elastolytic activity of macrophages [52].
Selected genetic-related factors  
associated with AAA
First reports on possible genetic background of AAA 
were published in 1977 when the article about three 
brothers, surgically treated for ruptured, previously 
symptomless AAA, was published [53]. 
In 2016 Bradley and colleagues performed a me-
ta-analysis and systematic review of the available litera-
ture to show which factors are genuine and which may 
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be caused by type 1 errors, biases, and differences in 
study design [54]. The most important genetic variants 
are described briefly as follow:
1. 9p21 rs10757278 — one of several polymorphism 
clustered together in a region of chromosome 9 that has 
been linked to increased risk of heart disease, abdominal 
obesity, dyslipidemia, hypertension and, potentially, di-
abetes. The overall estimate of heart disease cases that 
may involve this SNV (or related ones nearby) is said 
to be 20–30% [55]. Genome-wide association studies 
(GWAS) have identified a 9p21 as a major risk locus for 
coronary artery disease and myocardial infarction. All of 
the listed factors can lead to development of AAA [56].
2. SORT1 rs599839 — SORT1 gene on chromosome 1, 
carries information about protein called sortilin. Sortilin 
is a transmembrane protein primarily found in brain 
tissue. It is recognized as a major player in different 
processes of atherogenesis. Research results suggest 
that sortilin has a significant role in the pathogenesis of 
vascular and metabolic disorders through contributions 
to inflammation and calcification of arterial wall. More-
over, sortilin might play role in dysregulation of lipo-
protein metabolism and type II diabetes mellitus [57]. 
3. LRP1 rs1466535 — association between the 
rs1466535 SNV in the gene of low density lipoprotein 
receptor-related protein 1 (LRP1) and abdominal aortic 
aneurysm was showed by GWAS conducted by Bown 
et al. [58]. Later this association was also confirmed by 
a group of Italian scientists led by Silvia Galora and Claudia 
Saracini [59]. Despite the evidence provided by the two 
reports, it is not certain if the association is specific for 
aneurysmal disease or the atherosclerotic process [60]. 
4. MMP3 rs3025058 — SNV rs3025058 was first de-
scribed in 1995 as a variant located upstream of MMP3 
and influencing the regulation of this gene expression. 
The role of MMP3 proteinase was presented in previous 
sections of this review.
5. AGTR1 rs5186 — rs5186, a SNV, also, known as 
+1166A/C or A1166C is located in the 3’ untranslated 
region of AGTR1 mRNA. It is among the most studied 
of over 50 SNVs in AGTR1 [61]. AGTR1 is a part of the 
renin-angiotensin system. Its physiological role is reg-
ulation of blood pressure and the balance of fluids and 
salts in the body. Angiotensin II (created in renin-angio-
tensin cascade) binds to the AT1 receptor in the blood 
vessels and stimulates them to constrict what results 
in increased blood pressure. Binding of angiotensin II 
to the AT1 receptor also stimulates production of al-
dosterone, a hormone that triggers the absorption of 
water and salt in the kidneys. The increased amount 
of fluid in the body also increases blood pressure [62]. 
As listed previously, elevated blood pressure is a risk 
factor of AAA development. 
6. ACE rs4646994 — rs4646994 is one of four SNVs 
representing perhaps the best studied ACE snV. it is 
actually not a single nucleotide variant at all; instead, 
it is an insertion/deletion of an Alu repetitive element 
in an intron of the ACE gene. Alleles containing the 
insertion are called “I” alleles, and “D” alleles lack the 
repetitive element [63]. Function of angiotensin-con-
verting enzyme (ACE) is catalysis of the cleavage of the 
angiotensin I into the active octamer the angiotensin II, 
which contributes to hypertension by inducing smooth 
muscle in the vessels to constriction and renal tubule 
sodium reabsorption [64].
7. APOA1 rs964184 — The rs964184 (G;G) geno-
type is associated with hypertriglyceridemia [65]. The 
APOA1 encodes a protein called apolipoprotein A-I 
(apoA-I). It is a component of high-density lipoprotein 
(HDL). HDL is a molecule that transports cholesterol 
and phospholipids through the bloodstream from the 
body’s tissues to the liver. Once in the liver, cholesterol 
and phospholipids are redistributed to other tissues 
or removed from the body. ApoA-I attaches to cell 
membranes and promotes the movement of choles-
terol and phospholipids from inside the cell to the 
outer surface. Once outside the cell, these substances 
combine with ApoA-I to form HDL. ApoA-I also triggers 
a reaction called cholesterol esterification that converts 
cholesterol to a form that can be fully integrated into 
HDL and transported through the bloodstream. Hyper-
triglyceridemia, which can develop easier in a group of 
patients with this gene variant, is a one of many causes 
of atherosclerosis [65]. 
Summary and conclusions
1. The abdominal aortic aneurysm is the most common 
location for this condition. 
a) The risk of developing AAA increases with age. 
B) It is more common in men. AAA rupture is 
associated with a high risk of death.
2. Abdominal aortic aneurysm most often is asymp-
tomatic, which hinders its early detection and 
treatment.
3. The pathogenesis of AAA is complex and still not 
fully understood. The most important processes in 
the pathophysiology of AAA are degeneration and 
atherosclerosis of the arterial wall.
4. The factors involved in the pathogenesis of AAA and 
TAA are not quite the same.
5. Important compounds involved in the formation of 
AAA and increasing the risk of its rupture are some 
of the extracellular matrix metalloproteinases.
6. Genetic variants of numerous genes are associated 
with the risk of developing AAA.
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7. More research is needed into the pathogenesis of 
AAA and identification of biomarkers that would 
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